ReviewArchives of dermatological research2014
Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
Review in Archives of dermatological research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 73 citations in OpenAlex.
- Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy.Therapeutic advances in gastroenterology · 2025Review
- Dual Chemotherapeutic Loading in Oxalate Transferrin-Conjugated Polymersomes Incorporated into Chitosan Hydrogels for Site-Specific Targeting of Melanoma Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review).Oncology letters · 2024Review
- Biological characteristics and clinical management of uveal and conjunctival melanoma.Oncology research · 2024Review
- Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.The Journal of biological chemistry · 2022Article
- Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.Frontiers in immunology · 2022Review
- Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer.Molecular therapy. Nucleic acids · 2021Review
- Modulating T Follicular Cells In Vivo Enhances Antigen-Specific Humoral Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- How to select IgG subclasses in developing anti-tumor therapeutic antibodies.Journal of hematology & oncology · 2020Review
- Review
- Recombinant Expression and Purification of Extracellular Domain of the Programmed Cell Death Protein Receptor.Reports of biochemistry & molecular biology · 2020Article
- Antiprogramed cell death-1 therapy with microspheres for metastatic liver tumors.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
- AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.Head & neck · 2018Review
- Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.Oncogene · 2018Article
- Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.Cancer biomarkers : section A of Disease markers · 2018Article
- Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma.Scientifica · 2018Review
- Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.Molecular imaging and biology · 2017Article
- PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Oncotarget · 2016Article
- Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses.Oncoimmunology · 2016Article
- Pembrolizumab: A Review in Advanced Melanoma.Drugs · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Advanced melanoma presents a significant therapeutic challenge to clinicians. Many therapies for metastatic melanoma are limited by low response rates, severe toxicities, and/or relatively short response duration. Cancer immunotherapies that act as immune-checkpoint inhibitors to block the localized immune suppression mechanisms utilized by tumors are undergoing development and clinical trials. A clinically relevant immune escape mechanism in melanoma is the activation of the programmed cell death-1 (PD-1) receptor on infiltrating T cells. Activating PD-1 triggers an immune checkpoint resulting in inhibition of T cells directed against melanoma antigens and prevents the immune system from combating the melanoma. In Phase I clinical trials, two anti-PD1 therapies, Nivolumab and MK-3475, that block the PD-1 receptor to enable T cell killing have demonstrated objective tumor responses in patients with advanced melanoma. The purpose of this review is to present the available clinical evidence on anti-PD-1 and anti-PD-L1 immunotherapy for the treatment of advanced melanoma. We also discuss limitations associated with anti-PD-1 therapy. The blockade of the PD-1-PD-L1 pathway has shown promising results in clinical trials and has revolutionized melanoma immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.